Despite Alzheimer's disease (AD) incidence being projected to increase worldwide, the drugs currently on the market can only mitigate symptoms. Considering the failures of the classical paradigm "one target-one drug-one disease" in delivering effective medications for AD, polypharmacology appears to be a most viable therapeutic strategy. Polypharmacology can involve combinations of multiple drugs and/or single chemical entities modulating multiple targets. Taking inspiration from an ongoing clinical trial, this work aims to convert a promising cromolyn-ibuprofen drug combination into single-molecule "codrugs." Such codrugs should be able to similarly modulate neuroinflammatory and amyloid pathways, while showing peculiar pros and cons. By exploiting a linking strategy, we designed and synthesized a small set of cromolyn-ibuprofen conjugates (-). Preliminary plasma stability and neurotoxicity assays allowed us to select diamide and ethanolamide as promising compounds for further studies. We investigated their immunomodulatory profile in immortalized microglia cells, in vitro anti-aggregating activity towards Aβ-amyloid self-aggregation, and their cellular neuroprotective effect against Aβ-induced neurotoxicity. The fact that effectively reduced Aβ-induced neuronal death, prompted its investigation into an in vivo model. Notably, was demonstrated to significantly increase the longevity of Aβ-expressing and to improve fly locomotor performance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923232PMC
http://dx.doi.org/10.3390/molecules26041112DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
8
combinations single-molecule
4
single-molecule polypharmacology-cromolyn-ibuprofen
4
polypharmacology-cromolyn-ibuprofen conjugates
4
conjugates alzheimer's
4
disease despite
4
despite alzheimer's
4
disease incidence
4
incidence projected
4
projected increase
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!